Furan amide compound and application thereof

By developing new furanamide compounds to antagonize androgen receptors, the problem of mutations in existing drugs has been solved, and effective antagonism of androgen receptors has been achieved, especially in castration-resistant prostate cancer. The therapeutic effect is better than that in present-day prostate cancer There is medicine.

CN118994142AActive Publication Date: 2024-11-22JINHUA INSTITUTE OF ZHEJIANG UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202310577395.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-22
Estimated Expiration
2043-05-22

AI Technical Summary

Technical Problem

Existing androgen receptor antagonists are prone to lead to drug resistance mutations after long-term use, especially in the ligand-binding pocket area of ​​androgen receptors, resulting in reduced efficacy and limiting prostate cancer, especially castration-resistant prostate. Treatment options and benefits of cancer.

Method used

Develop a novel furanamide compound that blocks the signaling pathway of androgen receptors by antagonizing the ligand domain dimerization of androgen receptors, providing AR antagonists with a completely new structure and mechanism for the treatment of androgens Receptor-mediated diseases such as prostate cancer.

Benefits of technology

This compound has obvious antagonistic activity on androgen receptors, can effectively inhibit the activity in AR F877L/T878A double-point mutant cells, is better than the existing drugs enzalutamide and dalorutamide, and shows better safety It is suitable for the treatment of prostate cancer, breast cancer and ovarian cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994142A_ABST
    Figure CN118994142A_ABST
Patent Text Reader

Abstract

The invention discloses a furan amide compound and application thereof, and belongs to the technical field of medicines. The structural general formula of the furan amide compound is shown as a formula (I). The invention provides a novel furan amide AR antagonist, the compound and the derivative thereof have obvious antagonistic activity on androgen receptors and show better biological activity in in-vivo and in-vitro biological evaluation, the antagonistic activity of the androgen receptors is superior to that of enzalutamide, and the compound and the derivative thereof have good application prospects. The compound is effective in an AR F877L / T878A two-point mutation cell model resistant to enzalutamide, the activity of the compound is superior to that of Dacrolutamide, and the compound shows relatively good safety. Therefore, the compound can be used as an androgen receptor antagonist to be applied to treatment of androgen receptor related diseases, including but not limited to treatment of prostatic cancer, breast cancer, ovarian cancer and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to furanamide compounds and derivatives thereof, and uses thereof in preparing anti-tumor drugs, and in particular to uses thereof as androgen receptor antagonists in preparing drugs for treating prostate cancer. Background Art

[0002] Prostatic cancer is the second most common cancer in men worldwide and the fifth most deadly. In recent years, with the aging of the population and changes in people's dietary structure, the incidence and mortality of prostate cancer in my country have increased year by year. Therefore, prostate cancer has become a major "health killer" that seriously threatens human life.

[0003] The pathogenesis of prostate cancer is complex. It is a multi-stage progressive disease. According to the progression of the disease, it can be divided into localized, locally advanced, and metastatic prostate cancer. Localized prostate cancer can be cured by surgery, radiotherapy, and other methods. For locally advanced and metastatic prostate cancer, the first-line treatment strategy is androgen deprivation therapy (ADT), which uses gonadotropin-releasing hormone agonists or antagonists and CYP17A1 inhibitors. Both normal prostate cells and cancer cells rely on androgens for growth. Surgery or medical castration can greatly reduce the level of androgens in patients with early prostate cancer, thereby inhibiting the androgen-androgen receptor (AR)-dependent signaling pathway and ultimately inhibiting the growth of prostate cancer cells. However, after ADT treatment, most patients usually progress to castration-resistant prostate cancer (CRPC) within two years. The prognosis is poor, and the median survival time of patients is only 3-4 years. It is the most important factor causing death in prostate cancer patients.

[0004] At present, an important strategy for the clinical treatment of CRPC is to target the androgen receptor (AR). AR belongs to the nuclear receptor superfamily and consists of four domains, including the N-terminal domain, the DNA binding domain, the flexible hinge region and the C-terminal ligand binding domain. The ligand binding domain contains the ligand binding pocket (LBP), that is, the androgen binding pocket. Two generations of AR antagonists have been launched clinically. The first generation of drugs are flutamide, bicalutamide, and nilutamide, and the second generation includes enzalutamide, apalutamide and darolutamide. The above second-generation AR antagonists all target the ligand binding pocket (LBP) of AR, but long-term use of the drug will lead to mutations, resulting in drug resistance. At present, most of the drug-resistant mutations of androgen receptor occur in the ligand binding domain, especially concentrated in the ligand binding pocket, including F877L, T878A, H875Y and W742C. These drug-resistant mutations will directly affect the binding of the drug to the ligand binding pocket and reduce the efficacy. At the same time, when drug-resistant mutations occur, multidrug resistance often occurs, which severely limits the options and benefits of clinical treatment.

[0005] Therefore, searching for and discovering AR antagonists with novel structures and novel mechanisms will help overcome AR LBP mutation resistance and have important clinical value.

[0006] Inspired by the gain-of-function mutations of androgen insensitivity syndrome in the previous research of the inventor's team, molecular dynamics simulations and small-angle X-ray scattering experiments confirmed that the above mutations can destroy the dimerization of AR, thereby blocking the AR signaling pathway. Further analysis of the structure of the AR dimerization interface revealed a new binding pocket. For this binding pocket, a lead molecule was obtained after structure-based virtual screening and structural optimization, which has certain AR transcriptional inhibitory activity, see patent document CN113444081B. On this basis, the structure of the above lead molecule is optimized, and it is expected to obtain a new compound with further improved pharmacological activity. Summary of the invention

[0007] The object of the present invention is to provide a novel compound having androgen receptor antagonist activity, and to apply the compound to the preparation of a drug for treating androgen receptor-mediated diseases such as prostate cancer.

[0008] To achieve the above object, the present invention adopts the following technical solution:

[0009] The present invention provides a furanamide compound, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure as shown in formula (I):

[0010]

[0011] Wherein, R1 and R2 are selected from hydrogen, halogen, nitro, cyano, hydroxyl, amino, C 1-3 Alkyl, C 1-3 Fluorinated alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkoxy, C 1-3 Alkylamino, C 1-3 Dialkylamino, C 3-6 Cycloalkylamino, C 1-3 Alkylsulfone group;

[0012] R3 is selected from hydrogen, C 1-4 alkyl;

[0013] When X is O, Y and Z are selected from CH and N respectively, and at least one of Y and Z is N;

[0014] When X is S, Y is CH, and Z is N;

[0015] When X is N, Y is N or CH, and Z is S;

[0016] L is selected from -CH2-, -CO-;

[0017] G is selected from hydrogen, halogen, hydroxyl, C 1-4 Alkyl, C 1-4 Fluorinated alkyl, -NR4R5, -NH(CH2) n NR4R5, n = 1-3; R4 and R5 are independent of each other, may be the same or different, and are selected from hydrogen, acetyl, hydroxyethyl, hydroxypropyl, methylsulfonyl, C 1-4 Alkyl, C 1-4 Fluorinated alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl; or NR4R5 is a 3-8 membered cyclic amine or substituted cyclic amine selected from morpholine, thiomorpholine, thiomorpholine dioxide, piperazine, pyrrolidine, piperidine, and the substituent is selected from hydrogen, halogen, amino, cyano, isopropyl, acetyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, C 1-6 Alkyl, C 1-6 Fluorinated alkyl, C 1-6 Alkoxy, C 1-6 Fluorinated alkoxy, C 3-8 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Dialkylamino.

[0018] Preferably, in the furanamide compound, R1 and R2 are selected from H, F, Cl, Br, NO2, CN, CH3, CF3, CF3CH2, OCH3, OCHF2, OCF3, OCH2CHF2, OCH2CF3;

[0019] R3 is selected from H, CH3, CH2CH3;

[0020]

[0021] L is selected from -CH2-, -CO-;

[0022] G is selected from H, F, CH3, CH2CH3, CF3, NH2, NHCH3, N(CH3)2, N(CH2CH3)2, OH, OCH3, OCH2CH3,

[0023] More preferably, the structural formula of the furanamide compound is any one of A-1 to A-57, B-1 to B-18, C-1 to C-18, D-1 to D-6, E-1 to E-6, F-1 to F-6, and G-1 to G-6,

[0024]

[0025]

[0026]

[0027]

[0028]

[0029] The present invention also provides derivatives of the furanamide compounds, and pharmaceutically acceptable salts thereof or mixtures, tautomers, stereoisomers, solvates, metabolites, and prodrug molecules thereof.

[0030] The pharmaceutically acceptable salts include, but are not limited to, organic acid salts, inorganic acid salts, organic alkali salts, and inorganic alkali salts. The organic acid salts include, but are not limited to, oxalates, lactates, p-toluenesulfonates, malates, citrates, fumarates, camphorsulfonates, and methanesulfonates; the inorganic acid salts include, but are not limited to, nitrates, sulfates, hydrohalides, and phosphates. The organic alkali salts include, but are not limited to, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, triethylamine, tert-butylamine, and the like. The inorganic alkali salts include, but are not limited to, sodium hydroxide, potassium hydroxide, and lithium hydroxide, and the like.

[0031] The solvate refers to a complex with variable stoichiometry formed by a solute (the compound of formula (I) provided by the present invention) and a solvent. The solvent includes but is not limited to pharmaceutically acceptable solvents such as water, methanol, ethanol and acetic acid.

[0032] The present invention also provides polymorphs of the furanamide compound or its salt or its solvate. The furanamide compound or its salt or its solvate can show polymorphism, that is, it can produce different crystal forms and have different physical properties, such as density, stability and solubility. Different crystal forms and salt forms of drugs may affect their dissolution and absorption in the body, thereby affecting the clinical efficacy and safety of the drug to a certain extent. The present invention provides a polymorph that is easy to process and suitable for drug formulation by studying the polymorphs of the compound of formula (I).

[0033] The present invention has found that the furanamide compounds and their derivatives have significant antagonistic activity against androgen receptors, and exhibit good biological activity in both in vivo and in vitro biological evaluations. Therefore, the compounds can be applied to the treatment of tumors associated with abnormal expression or mutation of androgen receptors.

[0034] Specifically, the present invention provides the use of the furanamide compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrug molecules thereof, or polymorphs thereof in the preparation of androgen receptor antagonists.

[0035] The present invention also provides the use of the furanamide compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, or a polymorph thereof in the preparation of a drug for treating prostate cancer, breast cancer, or ovarian cancer. The prostate cancer includes but is not limited to metastatic prostate cancer and castration-resistant prostate cancer. It is worth noting that the pharmaceutical use of the compound is not limited to the preparation of drugs for the above-mentioned tumors.

[0036] The therapeutic mechanism of the drug includes: its effective ingredient furanamide compounds inhibit tumor cell proliferation by antagonizing androgen receptor activity, and further, furanamide compounds play an antagonistic role of androgen receptor by blocking dimerization of androgen receptor ligand domain.

[0037] The present invention also provides a pharmaceutical composition for treating tumors associated with abnormal expression or mutation of androgen receptor, which contains a therapeutically effective amount of one or more of the furanamide compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrug molecules thereof, or polymorphs thereof, and a pharmaceutically acceptable carrier.

[0038] The carrier is a commonly used excipient, filler, disintegrant, diluent, surfactant, absorption promoter, adsorption carrier, adhesive, lubricant, wetting agent, flavoring agent, sweetener, etc. in the pharmaceutical field. The pharmaceutical preparation of the present invention can be prepared according to conventional methods in the pharmaceutical field, including but not limited to capsules, powders, tablets, granules, pills, injections, syrups, oral liquids, inhalants, ointments, suppositories or patches.

[0039] The compounds provided by the present invention can be used in combination with existing anti-tumor drugs, including but not limited to microtubule protein degradation inhibitors (such as taxol), mitotic inhibitors (such as vinblastine, vindesine, etc.), antimetabolites (such as 5-fluorouracil, methotrexate, etc.), alkylating agents (cisplatin, carboplatin, etc.), insertable antibiotics (mitomycin, etc.), topoisomerase inhibitors (such as etoposide and camptothecin), biological response modifiers (such as interferon), proteasome inhibitors (such as bortezomib), etc.

[0040] The present invention has the following beneficial effects:

[0041] The present invention provides a novel furanamide AR antagonist. This type of compound and its derivatives have obvious antagonistic activity on androgen receptors, and show good biological activity in both in vivo and in vitro biological evaluations. Among them, dozens of compounds have better activity than enzalutamide, and are effective in the AR F877L / T878A double-point mutation cell model resistant to enzalutamide, with better activity than darolutamide, and show good safety. Therefore, this type of compound can be used as an androgen receptor antagonist in the treatment of diseases related to androgen receptors, including but not limited to the treatment of prostate cancer, metastatic prostate cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 The synthetic route of compounds A-1 to A-41 is shown in FIG.

[0043] Figure 2 The synthetic route of compound A-1 is shown in FIG.

[0044] Figure 3 The synthetic route of compounds A-42 to A-57 is shown in FIG.

[0045] Figure 4 The synthetic route of compound A-42.

[0046] Figure 5 The synthetic route of compounds B-1 to B-18.

[0047] Figure 6 The synthetic route of compound B-1 is shown in FIG.

[0048] Figure 7 The synthetic route of compounds C-1 to C-18 is shown in FIG.

[0049] Figure 8 The synthetic route of compound C-1.

[0050] Fig. 9 The synthetic route of compounds D-1 to D-6 is shown in FIG.

[0051] Fig.10 The synthetic route of compound D-1 is shown in FIG.

[0052] Fig.11 This is the synthetic route of compounds E-1~E-6, F-1~F-6, G-1~G-6.

[0053] Fig.12 The synthetic route of compound E-1 is shown in FIG. DETAILED DESCRIPTION

[0054] The present invention will be further described below in conjunction with specific embodiments. The specific embodiments are for illustration and should not be construed as limiting the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms also fall within the scope limited by the appended claims of the application.

[0055] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0056] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0057] Example 1: Preparation of target molecules A-1 to A-41

[0058] The synthetic routes of compounds A-1 to A-41 are as follows Figure 1 shown.

[0059] 1. Preparation of 2-methyl-N-(4-(pyrrolidin-1-ylmethyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-1), the specific synthetic route is as follows Figure 2 As shown, the method is as follows:

[0060] (a) Synthesis of 2-bromo-1-(3-trifluoromethylphenyl)ethan-1-one (Compound I-2-1)

[0061] Dissolve m-trifluoromethylacetophenone (I-1-1, 0.94 g, 5.0 mmol), N-bromosuccinimide (0.98 g, 5.5 mmol) and p-toluenesulfonic acid (0.43 g, 2.5 mmol) in acetonitrile (20 mL) and stir at 60°C for 1 h. Remove the solvent under reduced pressure, add an appropriate amount of water, extract with ethyl acetate, wash the organic layer with saturated saline solution, then dry with anhydrous Na2SO4, and concentrate under reduced pressure to obtain a crude product of light yellow oily liquid I-2-1 with a yield of 92%; ESI-MS: m / z=267.0[M+H] + .

[0062] (b) Synthesis of ethyl 2-acetyl-4-oxo-4-(3-trifluoromethylphenyl)butyrate (Compound I-3-1)

[0063] At 0°C, a solution of ethyl acetoacetate (439 mg, 4.2 mmol) in THF (10 mL) was added dropwise to a suspension of sodium hydride (60% w / w, 197 mg, 4.7 mmol) in anhydrous THF (20 mL). After stirring for half an hour, a solution of compound I-2-1 (1.25 g, 4.7 mmol) in THF (10 mL) was added dropwise, and then the mixture was moved to room temperature to react overnight. After adding an appropriate amount of water to the system for quenching, an appropriate amount of ethyl acetate was added, and the mixture was washed with water and saturated brine in turn. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a light yellow solid I-3-1 with a yield of 73%; 1 H NMR(500MHz,Chloroform-d)δ8.23(s,1H),8.17(d,J=8.0Hz,1H),7.85(d,J=8.0Hz,1H),7.63(t,J=8.0Hz,1H),4.30-4.20(m, 3H), 3.74 (dd, J=18.5, 8.0Hz, 1H), 3.52 (dd, J=18.5, 5.5Hz, 1H), 2.46 (s, 3H), 1.31 (t, J=7.0Hz, 3H); ESI-MS: m / z=317.1[M+H] + .

[0064] (c) Synthesis of ethyl 2-methyl-5-(3-trifluoromethylphenyl)furan-3-carboxylate (Compound I-4-1)

[0065] Under N2 protection, compound I-3-1 (946 mg, 3.0 mmol) was dissolved in acetonitrile (20 mL), trifluoromethanesulfonic acid (449 mg, 3.0 mmol) was added, and then the temperature was raised to 85°C for 1 h. An appropriate amount of ethyl acetate was added to the system, and the mixture was washed with water and saturated brine in sequence. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was subjected to column chromatography to obtain a light yellow solid I-4-1 with a yield of 78%; 1 H NMR(500MHz,Chloroform-d)δ7.90-7.87(m,1H),7.83-7.78(m,1H),7.56-7.46(m,2H),6.99 (s,1H),4.33(q,J=7.0Hz,2H),2.67(s,3H),1.38(t,J=7.0Hz,3H); ESI-MS:m / z=299.1[M+H] + .

[0066] (d) Synthesis of 2-methyl-5-(3-trifluoromethylphenyl)furan-3-carboxylic acid (Compound I-5-1)

[0067] Compound I-4-1 (600 mg, 2.22 mmol) was dissolved in ethanol and water (3:1, 20 mL), and sodium hydroxide (552 mg, 13.8 mmol) was added to react at room temperature overnight. Part of the solvent was removed under reduced pressure, and 2 mol / L dilute hydrochloric acid was added to the system to adjust the pH to 3-4, and white solid I-5-1 was obtained by suction filtration, with a yield of 90%; 1 H NMR (500MHz, DMSO-d6) δ12.76(s,1H),8.06-7.96(m,2H),7.71-7.62(m,2H),7.37(s,1H),2.62(s,3H).ESI-MS: m / z=271.1[M+H] + .

[0068] (e) Synthesis of 4-(pyrrolidin-1-ylmethyl)thiazol-2-amine (Compound I-7-1)

[0069] 2-Amino-4-chloromethylthiazole hydrochloride I-6 (740 mg, 4.0 mmol) and tetrahydropyrrole (500 μL, 6.0 mmol) were dissolved in acetonitrile (10 mL), and then triethylamine (1.11 mL, 8.0 mmol) was added, and the reaction was allowed to proceed overnight at room temperature. The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid I-7-1 with a yield of 81%; 1 H NMR (500MHz, DMSO-d6) δ7.12(s,2H),6.77(s,1H),4.09(s,2H),3.30(s,4H),1.92-1.88(m,4H).ESI-MS:m / z=184.1[M+H] + .

[0070] (f) Preparation of 2-methyl-N-(4-(pyrrolidin-1-ylmethyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-1)

[0071] Compound I-5-1 (270 mg, 1.0 mmol), compound I-7-1 (183 mg, 1.0 mmol), EDCI (382 mg, 2.0 mmol) and 4-PPY (15 mg, 0.1 mmol) were dissolved in DCM (10 mL) and refluxed with stirring overnight. The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid A-1 with a yield of 76%; 1H NMR(500MHz,DMSO-d6)δ12.26(s,1H),7.94-7.87(m,3H),7.76-7.69(m,2H), 7.11(s,1H),3.82(s,2H),2.70(s,7H),1.76(s,4H).ESI-MS:m / z=436.1[M+H] + .

[0072] 2. Preparation of N-(4-((3,3-difluoropyrrolidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-2)

[0073] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 3,3-difluoropyrrolidine to obtain a white solid with a yield of 68%; 1 H NMR(500MHz,DMSO-d6)δ12.26(s,1H),7.94-7.85(m,3H),7.76-7.68(m,2H),7.06(s,1H),3.69(s, 2H),2.97(s,2H),2.77(s,2H),2.70(s,3H),2.25(tt,J=14.8,6.9Hz,2H).ESI-MS:m / z=471.2[M+H] + .

[0074] 3. Preparation of N-(4-((3-hydroxypyrrolidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-3)

[0075] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 3-hydroxypyrrolidine to obtain a white solid with a yield of 61%; 1 H NMR(500MHz,DMSO-d6)δ12.26(s,1H),8.04-7.81(m,3H),7.77-7.62(m,2H),7.13(s,1H),4.91(s,1H), 4.25(s,1H),3.84(s,2H),3.06-2.55(m,7H),2.06-1.95(m,1H),1.63(s,1H).ESI-MS: m / z=452.1[M+H] + .

[0076] 4. Preparation of N-(4-((dimethylamino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-4)

[0077] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced by dimethylamino to obtain a white solid with a yield of 56%; 1 HNMR(500MHz,DMSO-d6)δ12.28(s,1H),(t,J=1.9Hz,1H),8.07–7.89(m,3H),7.67–7.5 6(m,2H),7.02(s,1H),3.62(s,2H),2.73(s,6H),2.61(s,3H).ESI-MS:m / z=410.1[M+H] + .

[0078] 5. Preparation of N-(4-((diethylamino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-5)

[0079] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with diethylamino to obtain a white solid with a yield of 63%; 1 HNMR(500MHz,DMSO-d6)δ12.23(s,1H),7.94-7.86(m,3H),7.76-7.67(m,2H),7.04( s,1H),3.66(s,2H),2.70(s,3H),2.57(s,4H),1.03(s,6H).ESI-MS:m / z=438.1[M+H] + .

[0080] 6. Preparation of 2-methyl-N-(4-methylthiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-6)

[0081] Referring to the synthesis of compound A-1, 4-(pyrrolidin-1-ylmethyl)thiazol-2-amine (I-7-1) was replaced with 4-methylthiazol-2-amine to obtain a white solid with a yield of 83%; 1 H NMR(500MHz,DMSO-d6)δ12.17(s,1H),7.93-7.82(m,3H),7.75-7.66(m,2H),6.8 1(d,J=1.2Hz,1H),2.70(s,3H),2.31(d,J=1.1Hz,3H).ESI-MS:m / z=367.1[M+H] + .

[0082] 7. Preparation of 2-methyl-N-(4-(piperidin-1-ylmethyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-7)

[0083] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with piperidine to obtain a white solid with a yield of 52%; 1 H NMR(500MHz,DMSO-d6)δ12.26(s,1H),7.93-7.86(m,3H),7.75-7.68(m,2H),6.98(s,1H),3.4 8(s,2H),2.70(s,3H),2.40(s,4H),1.50(m,4H),1.42-1.34(m,2H).ESI-MS:m / z=450.1[M+H] + .

[0084] 8. Preparation of N-(4-((4,4-difluoropiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-8)

[0085] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 4,4-difluoropiperidine to obtain a white solid with a yield of 78%; 1 H NMR(500MHz,DMSO-d6)δ12.28(s,1H),7.95-7.85(m,3H),7.76-7.67(m,2H),7.05(s,1H),3.60(s,2H),2.70(s,3H),2.56(t,J=5.7Hz,4H),2.01 -1.91(m,4H).ESI-MS:m / z=486.1[M+H] + .

[0086] 9. Preparation of N-(4-((4,4-difluoropiperidin-1-yl)methyl)thiazol-2-yl)-5-(3-methoxyphenyl)-2-methylfuran-3-carboxamide (Compound A-9)

[0087] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-methoxyacetophenone, and tetrahydropyrrole was replaced by 4,4-difluoropiperidine to obtain a white solid with a yield of 76%; ESI-MS: m / z=448.1 [M+H] + .

[0088] 10. Preparation of N-(4-((4,4-difluoropiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethoxy)phenyl)furan-3-carboxamide (Compound A-10)

[0089] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-trifluoromethoxyacetophenone, and tetrahydropyrrole was replaced by 4,4-difluoropiperidine to obtain a white solid with a yield of 65%; ESI-MS: m / z=502.1 [M+H]+ .

[0090] 11. Preparation of 5-(3-(difluoromethoxy)phenyl)-N-(4-((4,4-difluoropiperidin-1-yl)methyl)thiazol-2-yl)-2-methylfuran-3-carboxamide (Compound A-11)

[0091] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-difluoromethoxyacetophenone, and tetrahydropyrrole was replaced by 4,4-difluoropiperidine to obtain a white solid with a yield of 60%; ESI-MS: m / z=484.1 [M+H] + .

[0092] 12. Preparation of 5-(3-cyanophenyl)-N-(4-((4,4-difluoropiperidin-1-yl)methyl)thiazol-2-yl)-2-methylfuran-3-carboxamide (Compound A-12)

[0093] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-cyanoacetophenone, and tetrahydropyrrole was replaced by 4,4-difluoropiperidine to obtain a white solid with a yield of 79%; ESI-MS: m / z=443.1 [M+H] + .

[0094] 13. Preparation of 2-methyl-5-(3-(trifluoromethyl)phenyl)-N-(4-((4-(trifluoromethyl)piperidin-1-yl)methyl)thiazol-2-yl)furan-3-carboxamide (Compound A-13)

[0095] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with p-trifluoromethylpiperidine to obtain a white solid with a yield of 66%; 1 H NMR(500MHz,DMSO-d6)δ12.27(s,1H),7.97-7.84(m,3H),7.77-7.66(m,2H),7.02(s,1H),3.53(s,2H),2.95(d,J=11.2Hz,2H) ,2.70(s,3H),2.32-2.19(m,1H),2.09-1.97(m,2H),1.84-1.73(m,2H),1.45(qd,J=12.4,4.0Hz,2H).ESI-MS:m / z=518.1[M+H] + .

[0096] 14. Preparation of N-(4-((4-(dimethylamino)piperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-14)

[0097] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with p-dimethylaminopiperidine to obtain a white solid with a yield of 52%; 1 H NMR(500MHz,DMSO-d6)δ12.25(s,1H),7.94-7.86(m,3H),7.72-7.69(m,2H),6.98(s,1H),3.48(s,2H),2.92-2.86(m,2H),2.70(s,3H),2.19( s,6H),2.09(s,1H),1.98(td,J=11.6,2.3Hz,2H),1.72(d,J=11.9Hz,2H),1.63(p,J=6.0Hz,1H),1.42-1.38(m,1H).ESI-MS:m / z=493.2[M+H] + .

[0098] 15. Preparation of N-(4-((4-methoxypiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-15)

[0099] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with p-methoxypiperidine to obtain a white solid with a yield of 77%; 1 H NMR(500MHz,DMSO-d6)δ12.27(s,1H),7.93-7.86(m,3H),7.76-7.69(m,2H),7.00(s,1H),3.50(s,2H),3.21(s, 3H),3.16(s,1H),2.70(s,5H),2.15(s,2H),1.82(d,J=10.5Hz,2H),1.47-1.35(m,2H).ESI-MS:m / z=480.1[M+H] + .

[0100] 16. Preparation of N-(4-((4-hydroxypiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-16)

[0101] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with p-hydroxypiperidine to obtain a white solid with a yield of 60%; 1HNMR(500MHz,DMSO-d6)δ12.26(s,1H),7.95-7.85(m,3H),7.76-7.68(m,2H),7.07-6.91(m,1H),4.55(s,1H),3.4 7(d,J=22.2Hz,3H),2.70(s,5H),2.11(s,2H),1.71(d,J=11.6Hz,2H),1.45-1.35(m,2H).ESI-MS:m / z=466.1[M+H] + .

[0102] 17. Preparation of N-(4-((4-hydroxypiperidin-1-yl)methyl)thiazol-2-yl)-5-(3-methoxyphenyl)-2-methylfuran-3-carboxamide (Compound A-17)

[0103] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-methoxyacetophenone, and tetrahydropyrrole was replaced by 4-hydroxypiperidine to obtain a white solid with a yield of 68%; ESI-MS: m / z=428.1 [M+H] + .

[0104] 18. Preparation of N-(4-((4-hydroxypiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethoxy)phenyl)furan-3-carboxamide (Compound A-18)

[0105] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-trifluoromethoxyacetophenone, and tetrahydropyrrole was replaced by 4-hydroxypiperidine to obtain a white solid with a yield of 61%; ESI-MS: m / z=482.1 [M+H] + .

[0106] 19. Preparation of 5-(3-(difluoromethoxy)phenyl)-N-(4-((4-hydroxypiperidin-1-yl)methyl)thiazol-2-yl)-2-methylfuran-3-carboxamide (A-19)

[0107] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-difluoromethoxyacetophenone, and tetrahydropyrrole was replaced by 4-hydroxypiperidine to obtain a white solid with a yield of 58%; ESI-MS: m / z=464.1 [M+H] + .

[0108] 20. Preparation of N-(4-((3-hydroxypiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-20)

[0109] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 3-hydroxypiperidine to obtain a white solid with a yield of 66%; ESI-MS: m / z = 466.1 [M+H] + .

[0110] 21. Preparation of N-(4-((2-hydroxypiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-21)

[0111] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 2-hydroxypiperidine to obtain a white solid with a yield of 60%; ESI-MS: m / z = 466.1 [M+H] + .

[0112] 22. Preparation of N-(4-((4-(hydroxymethyl)piperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-22)

[0113] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with p-hydroxymethylpiperidine to obtain a white solid with a yield of 71%; 1 H NMR(500MHz,DMSO-d6)δ12.27(s,1H),7.96-7.84(m,3H),7.76-7.67(m,2H),6.99(s,1H),4.41(s,1H),3.50(s,2H),3.24(d,J=6.2Hz,2H) ,2.86(d,J=27.8Hz,2H),2.70(s,3H),1.97(s,2H),1.64(d,J=12.5Hz,2H),1.37-1.30(m,1H),1.21-1.08(m,2H).ESI-MS:m / z=480.1[M+H] + .

[0114] 23. Preparation of N-(4-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-23)

[0115] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 2-(4-piperidinyl)-2-propanol to obtain a white solid with a yield of 66%; 1H NMR(500MHz,DMSO-d6)δ12.27(s,1H),7.98–7.81(m,3H),7.76-7.69(m,2H),7.04(s,1H),4.07(s,1H),3.75-3.41(m,2H),3.00 (s,2H),2.70(s,3H),2.08(d,J=94.7Hz,2H),1.65(d,J=19.2Hz,2H),1.38-1.27(m,3H),1.02(s,6H).ESI-MS:m / z=508.1[M+H] + .

[0116] 24. Preparation of 2-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-24)

[0117] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 4-methylpiperazine to obtain a white solid with a yield of 72%; 1 HNMR(500MHz,DMSO-d6)δ12.27(s,1H),8.00-7.82(m,3H),7.77-7.66(m,2H),7.00( s,1H),3.50(s,2H),2.70(s,3H),2.44(s,8H),2.17(s,3H).ESI-MS:m / z=465.1[M+H] + .

[0118] 25. Preparation of N-(4-((4-ethylpiperazin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-25)

[0119] Preparation of target compound A-25 Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 4-ethylpiperazine to obtain a white solid with a yield of 74%; 1 H NMR(500MHz,DMSO-d6)δ12.27(s,1H),7.95-7.85(m,3H),7.75-7.69(m,2H),7.00(s,1H),3. 50(s,2H),2.70(s,3H),2.50-2.14(m,10H),0.98(t,J=7.2Hz,3H).ESI-MS:m / z=479.1[M+H] + .

[0120] 26. Preparation of N-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-26)

[0121] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with N-hydroxyethylpiperazine to obtain a white solid with a yield of 64%; 1 H NMR(500MHz,DMSO-d6)δ12.26(s,1H),7.98-7.85(m,3H),7.76-7.69(m,2H),7.00(s,1H),4. 40(s,1H),3.50(d,J=9.2Hz,4H),2.70(s,3H),2.50-2.15(m,11H).ESI-MS:m / z=495.1[M+H] + .

[0122] 27. Preparation of N-(4-((4-acetylpiperazin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-27)

[0123] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 4-acetylpiperazine to obtain a white solid with a yield of 73%; 1 HNMR(500MHz,DMSO-d6)δ12.29(s,1H),7.94-7.87(m,3H),7.76-7.67(m,2H),7.05(s,1H) ,3.55(s,6H),2.70(s,3H),2.41(d,J=22.0Hz,4H),1.98(s,3H).ESI-MS:m / z=493.1[M+H] + .

[0124] 28. Preparation of 2-methyl-N-(4-(morpholinomethyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-28)

[0125] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with morpholine to obtain a white solid with a yield of 81%; 1H NMR(500MHz,Chloroform-d)δ9.75(s,1H),7.89-7.85(m,1H),7.77(dt,J=7.2,1.9Hz,1H),7.58-7.51(m,2H),6.86(s,1 H),6.82(s,1H),3.72(t,J=4.7Hz,4H),3.55-3.51(m,2H),2.77(s,3H),2.47(t,J=4.4Hz,4H).ESI-MS:m / z=452.1[M+H] + .

[0126] 29. Preparation of 2-methyl-N-(4-(morpholinomethyl)thiazol-2-yl)-5-(3-(trifluoromethoxy)phenyl)furan-3-carboxamide (Compound A-29)

[0127] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-trifluoromethoxyacetophenone, and tetrahydropyrrole was replaced by morpholine to obtain a white solid with a yield of 76%; 1 H NMR(500MHz,DMSO-d6)δ12.29(s,1H),7.82(s,1H),7.67-7.60(m,2H),7.54-7.49(m,1H),7.34(m,1H),7.0 3(s,1H),3.58(t,J=4.6Hz,4H),3.51(s,2H),2.69(s,3H),2.42(t,J=4.6Hz,4H).ESI-MS:m / z=468.1[M+H] + .

[0128] 30. Preparation of 5-(3-(difluoromethoxy)phenyl)-2-methyl-N-(4-(morpholinomethyl)thiazol-2-yl)furan-3-carboxamide (Compound A-30)

[0129] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-difluoromethoxyacetophenone, and tetrahydropyrrole was replaced by morpholine to obtain a white solid with a yield of 80%; 1 H NMR (500MHz, DMSO-d6) δ12.30(s,1H),7.78(s,1H),7.56-7.48(m,2H),7.37(t,J=2.0Hz,1H),7.33(s,1H),7.15(m, 1H),7.02(s,1H),3.58(t,J=4.6Hz,4H),3.51(s,2H),2.69(s,3H),2.42(t,J=4.6Hz,4H).ESI-MS:m / z=450.1[M+H] + .

[0130] 31. Preparation of 5-(3-methoxyphenyl)-2-methyl-N-(4-(morpholinomethyl)thiazol-2-yl)furan-3-carboxamide (Compound A-31)

[0131] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-methoxyacetophenone, and tetrahydropyrrole was replaced by morpholine to obtain a white solid with a yield of 69%; ESI-MS: m / z=414.1 [M+H] + .

[0132] 32. Preparation of 5-(3-cyanophenyl)-2-methyl-N-(4-(morpholinomethyl)thiazol-2-yl)furan-3-carboxamide (Compound A-32)

[0133] Referring to the synthesis of compound A-1, m-trifluoromethylacetophenone was replaced by m-cyanoacetophenone, and tetrahydropyrrole was replaced by morpholine to obtain a white solid with a yield of 62%; ESI-MS: m / z=409.1 [M+H] + .

[0134] 33. Preparation of N-(4-(((2S,6R)-2,6-dimethylmorpholino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-33)

[0135] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with (2S,6R)-2,6-dimethylmorpholine to obtain a white solid with a yield of 70%; 1 H NMR(500MHz,DMSO-d6)δ12.27(s,1H),7.94-7.86(m,3H),7.75-7.69(m,2H),7.02(s,1H),3.61-3 .43(m,4H),2.70(s,5H),1.71(t,J=10.4Hz,2H),1.04(d,J=6.3Hz,6H).ESI-MS:m / z=480.1[M+H] + .

[0136] 34. Preparation of 2-methyl-N-(4-(thiomorpholinomethyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-34)

[0137] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with thiomorpholine to obtain a white solid with a yield of 82%; 1HNMR(500MHz,DMSO-d6)δ12.28(s,1H),7.93-7.87(m,3H),7.75-7.69(m,2H),7.02(s,1H) ,3.54(s,2H),2.69(d,J=4.8Hz,7H),2.61(dd,J=5.9,3.9Hz,4H).ESI-MS:m / z=468.1[M+H] + .

[0138] 35. Preparation of N-(4-((1,1-dioxothiomorpholino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-35)

[0139] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with thiomorpholine-1,1-dioxide to obtain a white solid with a yield of 74%; 1 H NMR(500MHz,DMSO-d6)δ12.29(s,1H),7.97-7.86(m,3H),7.77-7.68(m,2H),7.12(s,1H) ,3.75(s,2H),3.13(d,J=5.9Hz,4H),2.98(s,4H),2.70(s,3H).ESI-MS:m / z=500.1[M+H] + .

[0140] 36. Preparation of N-(4-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-36)

[0141] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 2-aminoethanol to obtain a white solid with a yield of 63%; 1 HNMR(500MHz,DMSO-d6)δ7.90(dd,J=17.0,6.6Hz,3H),7.77-7.65(m,2H),7.03(s,1H), 4.62(s,1H),3.81(s,2H),3.52(t,J=5.6Hz,2H),2.70(s,5H).ESI-MS:m / z=426.1[M+H] + .

[0142] 37. Preparation of N-(4-(((2-hydroxyethyl)(methyl)amino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-37)

[0143] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 2-methylaminoethanol to obtain a white solid with a yield of 68%; ESI-MS: m / z = 440.1 [M+H] + .

[0144] 38. Preparation of (R)-N-(4-(((1-hydroxypropan-2-yl)amino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-38)

[0145] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with (R)-2-aminopropane-1-ol to obtain a white solid with a yield of 60%; ESI-MS: m / z=440.1 [M+H] + .

[0146] 39. Preparation of N-(4-(((3-hydroxypropyl)amino)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-39)

[0147] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced with 3-amino-1-propanol to obtain a white solid with a yield of 56%; 1 H NMR(500MHz,DMSO-d6)δ7.91(dd,J=19.0,7.5Hz,3H),7.76-7.69(m,2H),7.28(s,1H),4.06(s,2H),3 .49(t,J=6.1Hz,2H),2.95(t,J=7.6Hz,2H),2.70(s,3H),1.78-1.69(m,2H).ESI-MS:m / z=440.1[M+H] + .

[0148] 40. Preparation of 2-methyl-N-(4-(((2-morpholinethyl)amino)methyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-40)

[0149] Referring to the synthesis of compound A-1, tetrahydropyrrole was replaced by N-(2-aminoethyl)morpholine to obtain a white solid with a yield of 68%; ESI-MS: m / z=495.1 [M+H] + .

[0150] 41. Preparation of N-(4-(hydroxymethyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-41)

[0151] Referring to the synthesis of compound A-1, 4-(pyrrolidin-1-ylmethyl)thiazol-2-amine (I-7-1) was replaced with 2-amino-4-hydroxymethylthiazole to obtain a white solid with a yield of 70%; 1 H NMR(500MHz,DMSO-d6)δ8.09-8.03(m,2H),7.69-7.64(m,2H),7.45(s,1H),7.0 4(s,2H),6.64(s,1H),5.11-5.02(m,2H),2.65(s,3H).ESI-MS:m / z=383.1[M+H] + .

[0152] Example 2: General method for preparing target molecules A-42 to A-57

[0153] The synthetic routes of compounds A-42 to A-57 are as follows Figure 3 shown.

[0154] 1. Preparation of compound A-42, the synthetic route is as follows Figure 4 As shown, the method is as follows:

[0155] (a) Synthesis of (2-aminothiazol-4-yl)(3,3-difluoropyrrolidin-1-yl)methanone (I-7-a-1)

[0156] 2-aminothiazole-4-carboxylic acid (I-6-a, 720 mg, 5.0 mmol), 3,3-difluoropyrrolidine (710 μL, 7.5 mmol) and HATU (3.80 g, 10.0 mmol) were dissolved in DMF (15 mL), and then DIPEA (2.6 mL, 15.0 mmol) was added dropwise to the reaction system and stirred at room temperature overnight. An appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid 1-7-a-1 with a yield of 88%; ESI-MS: m / z=234.0 [M+H] + .

[0157] (b) Preparation of N-(4-(3,3-difluoropyrrolidine-1-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-42)

[0158] Compound I-5-1 (270 mg, 1.0 mmol), compound I-7-a-1 (233 mg, 1.0 mmol), EDCI (382 mg, 2.0 mmol) and 4-PPY (15 mg, 0.1 mmol) were dissolved in DCM (10 mL) and refluxed with stirring overnight. The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid A-42 with a yield of 78%; ESI-MS: m / z=486.1 [M+H] + .

[0159] 2. Preparation of N-(4-(4,4-difluoropiperidine-1-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-43)

[0160] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced by 4,4-difluoropiperidine to obtain a white solid with a yield of 81%; ESI-MS: m / z=500.1 [M+H] + .

[0161] 3. Preparation of N-(4-(4-hydroxypiperidine-1-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-44)

[0162] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with 4-hydroxypiperidine to obtain a white solid with a yield of 76%; ESI-MS: m / z = 480.1 [M+H] + .

[0163] 4. Preparation of N-(4-(4-(hydroxymethyl)piperidine-1-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-45)

[0164] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with p-hydroxymethylpiperidine to obtain a white solid with a yield of 70%; ESI-MS: m / z=494.1 [M+H] + .

[0165] 5. Preparation of 2-methyl-N-(4-(4-methylpiperazine-1-carbonyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-46)

[0166] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with 4-methylpiperazine to obtain a white solid with a yield of 79%; ESI-MS: m / z=479.1 [M+H] + .

[0167] 6. Preparation of 2-methyl-N-(4-(morpholine-4-carbonyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-47)

[0168] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with morpholine to obtain a white solid with a yield of 87%; 1 H NMR (500MHz, DMSO-d6) δ12.40(s,1H),7.96-7.87(m,3H),7.76-7.70(m,2H),7.67(s,1H),2.71(s,3H).ESI-MS: m / z=466.1[M+H] + .

[0169] 7. Preparation of 2-methyl-N-(4-(morpholine-4-carbonyl)thiazol-2-yl)-5-(3-(trifluoromethoxy)phenyl)furan-3-carboxamide (Compound A-48)

[0170] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced by morpholine, and trifluoromethylacetophenone was replaced by trifluoromethoxyacetophenone to obtain a white solid with a yield of 80%; ESI-MS: m / z=482.1 [M+H] + .

[0171] 8. Preparation of 5-(3-(difluoromethoxy)phenyl)-2-methyl-N-(4-(morpholine-4-carbonyl)thiazol-2-yl)furan-3-carboxamide (Compound A-49)

[0172] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced by morpholine, and trifluoromethylacetophenone was replaced by difluoromethoxyacetophenone to obtain a white solid with a yield of 71%; ESI-MS: m / z=464.1 [M+H] + .

[0173] 9. Preparation of N-(4-(4-acetylpiperazine-1-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-50)

[0174] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with acetylpiperazine to obtain a white solid with a yield of 75%; 1H NMR(500MHz,DMSO-d6)δ12.43(s,1H),7.95-7.88(m,3H),7.75-7.69(m,2H), 7.67(s,1H),3.51(s,4H),2.71(s,3H),2.04(s,3H).ESI-MS:m / z=507.1[M+H] + .

[0175] 10. Preparation of N-(4-(4-(2-hydroxyethyl)piperazine-1-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-51)

[0176] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with N-hydroxyethylpiperazine to obtain a white solid with a yield of 62%; ESI-MS: m / z=509.1 [M+H] + .

[0177] 11. Preparation of N-(4-(4-(dimethylamino)piperidine-1-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-52)

[0178] Preparation of target compound A-52 Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced by 4-dimethylaminopiperidine to obtain a white solid with a yield of 54%; ESI-MS: m / z = 507.1 [M+H] + .

[0179] 12. Preparation of 2-methyl-N-(4-(thiomorpholine-4-carbonyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-53)

[0180] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with thiomorpholine to obtain a white solid with a yield of 68%; ESI-MS: m / z = 482.1 [M+H] + .

[0181] 13. Preparation of N-(4-(1,1-dioxothiomorpholine-4-carbonyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound A-54)

[0182] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with thiomorpholine 1,1-dioxide to obtain a white solid with a yield of 80%; 1H NMR(500MHz,DMSO-d6)δ12.40(s,1H),7.96-7.91(m,2H),7.86(s,1H),7.77(s,1H),7.75-7.7 0(m,2H),4.03(d,J=7.1Hz,4H),3.28(t,J=5.3Hz,4H),2.71(s,3H).ESI-MS:m / z=514.1[M+H] + .

[0183] 14. Preparation of N-(2-hydroxyethyl)-2-(2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamido)thiazole-4-carboxamide (Compound A-55)

[0184] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with 2-aminoethanol to obtain a white solid with a yield of 66%; ESI-MS: m / z = 440.1 [M+H] + .

[0185] 15. Preparation of N-(2-hydroxyethyl)-N-methyl-2-(2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamido)thiazole-4-carboxamide (Compound A-56)

[0186] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with 2-methylaminoethanol to obtain a white solid with a yield of 60%; ESI-MS: m / z = 454.1 [M+H] + .

[0187] 16. Preparation of 2-(2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamido)-N-(methylsulfonyl)thiazole-4-carboxamide (Compound A-57)

[0188] Referring to the synthesis of compound A-42, 3,3-difluoropyrrolidine was replaced with methylsulfonamide to obtain a white solid with a yield of 72%; ESI-MS: m / z = 474.0 [M+H] + .

[0189] Example 3: General method for preparing target molecules B-1 to B-18

[0190] The synthetic routes of compounds B-1 to B-18 are as follows Figure 5 shown.

[0191] 1. Preparation of compound B-1, the synthetic route is as follows Figure 6 shown.

[0192] (a) Synthesis of 5-bromofuran-3-carboxylic acid (Compound II-2)

[0193] 3-furoic acid (II-1, 200 mg, 1.79 mmol), pyridinium bromide (0.63 g, 1.97 mmol) and glacial acetic acid (3 mL) were added to a reaction flask and heated to 50°C for overnight reaction. The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, the organic layers were combined, and dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid II-2 with a yield of 70%; ESI-MS: m / z = 191.0 [M+H] + .

[0194] (b) Synthesis of 5-(3-(trifluoromethyl)phenyl)furan-3-carboxylic acid (Compound II-3)

[0195] Under N2 protection, a mixed solvent of DME (15 mL) and water (3 mL) was added to a double-necked flask containing m-trifluoromethylphenylboronic acid (340 mg, 1.79 mmol), compound II-2 (340 mg, 1.79 mmol), sodium carbonate (450 mg, 5.39 mmol) and tetrakis(triphenylphosphine)palladium (105 mg, 0.08 mmol), and the temperature was raised to 90°C for 2 h. After cooling to room temperature, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, the organic layers were combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid II-3 with a yield of 65%; 1 H NMR(500MHz,Chloroform-d)δ8.17(d,J=1.0Hz,1H),7.96-7.93(m,1H),7.88-7 .84(m,1H),7.61-7.53(m,2H),7.10(d,J=1.0Hz,1H); ESI-MS:m / z=257.0[M+H] + .

[0196] (c) Preparation of N-(4-((diethylamino)methyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound B-1)

[0197] Compound II-3 (256 mg, 1.0 mmol), 4-((diethylamino)methyl)thiazole-2-amine (II-4, 185 mg, 1.0 mmol), EDCI (382 mg, 2.0 mmol) and 4-PPY (15 mg, 0.1 mmol) were dissolved in DCM (10 mL) and refluxed with stirring overnight (compound II-4 was prepared from compound I-6 and diethylamino as raw materials according to the same synthetic method of compound I-7-1). The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid B-1 with a yield of 72%; ESI-MS: m / z=424.1 [M+H] + .

[0198] 2. Preparation of target molecules B-2 to B-18

[0199] Referring to the synthesis of compound B-1, compound II-3 and 2-amino-4-chloromethylthiazole hydrochloride (I-6) were used as raw materials, and 3,3-difluoropyrrolidine, 3-hydroxypyrrolidine, piperidine, 4,4-difluoropiperidine, 4-hydroxypiperidine, 4-hydroxymethylpiperidine, 4-methylpiperazine, 4-acetylpiperazine, N-hydroxyethylpiperazine, 4-dimethylaminopiperidine, morpholine, (2S,6R)-2,6-dimethylmorpholine, thiomorpholine and thiomorpholine dioxide were used to replace diethylamino to prepare compounds B-2 to B-15;

[0200] Referring to the synthesis of compound B-1, compound II-3 and 2-aminothiazole-4-carboxylic acid (I-6-a) were used as raw materials, and 4-hydroxypiperidine, morpholine and thiomorpholine were used to replace diethylamino, respectively, to prepare compounds B-16 to B-18.

[0201] The chemical structures and ESI-MS results of the above compounds are shown in Table 1.

[0202] Table 1. Chemical structures of representative B-series target molecules

[0203]

[0204]

[0205] Example 4: General method for preparing target molecules C-1 to C-18

[0206] The synthetic routes of compounds C-1 to C-18 are as follows Figure 7 shown.

[0207] 1. Preparation of compound C-1, the synthetic route is as follows Figure 8 As shown, the method is as follows:

[0208] (a) 5-amino-1,3,4-thiadiazole-2-carboxylic acid (Compound III-2)

[0209] Dissolve 2-amino-1,3,4-thiadiazole-5-carboxylic acid ethyl ester (III-1, 865 mg, 5.0 mmol) in ethanol (20 mL), then add an aqueous solution of sodium hydroxide (5 M, 10 mL, 50 mmol) and stir at room temperature overnight. Remove part of the solvent under reduced pressure, add 2 mol / L dilute hydrochloric acid to the system to adjust the pH to 3-4, and filter to obtain white solid III-2 with a yield of 93%; ESI-MS: m / z = 146.0 [M+H] + .

[0210] (b) 5-amino-1,3,4-thiadiazol-2-yl-(3,3-difluoropyrrolidin-1-yl)methanone (Compound III-3-1)

[0211] Compound III-2 (580 mg, 4.0 mmol), 3,3-difluoropyrrolidine (570 μL, 6.0 mmol) and HATU (3.04 g, 8.0 mmol) were dissolved in DMF (20 mL), and then DIPEA (2.08 mL, 12.0 mmol) was added dropwise to the reaction system and stirred at room temperature overnight. An appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried with anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid III-3 with a yield of 78%; ESI-MS: m / z=235.0 [M+H] + .

[0212] (c) 5-((3,3-difluoropyrrolidin-1-yl)methyl)-1,3,4-thiadiazole-2-amine (Compound III-4-1)

[0213] At 0°C, compound III-3-1 (468 mg, 2.0 mmol) was dissolved in THF (10 mL), and then BH3-THF (1 M, 20 mL, 20.0 mmol) was slowly added dropwise. The reaction was continued for 30 min after the addition was completed, and then heated to 60°C for 3 h. After cooling to room temperature, 2M HCl was added, and the reaction was continued at 70°C for 2 h. After cooling to room temperature, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and then dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain white solid III-4-1 with a yield of 60%; ESI-MS: m / z=221.0 [M+H] + .

[0214] (d) N-(5-((3,3-difluoropyrrolidin-1-yl)methyl)-1,3,4-thiadiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound C-1)

[0215] Compound III-4-1 (220 mg, 1.0 mmol), compound I-5-1 (270 mg, 1.0 mmol), EDCI (382 mg, 2.0 mmol) and 4-PPY (15 mg, 0.1 mmol) were dissolved in DCM (10 mL) and refluxed with stirring overnight. The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid C-1 with a yield of 66%; ESI-MS: m / z=473.1 [M+H] + .

[0216] 2. Preparation of target molecules C-2 to C-18

[0217] Using compound III-2 as a raw material, 3-hydroxypyrrolidine, 4,4-difluoropiperidine, p-trifluoromethylpiperidine, 4-methoxypiperidine, 4-hydroxypiperidine, 4-hydroxymethylpiperidine, 4-methylpiperazine, N-hydroxyethylpiperazine, 4-acetylpiperazine, morpholine, (2S, 6R)-2,6-dimethylmorpholine, thiomorpholine, thiomorpholine dioxide, 4-dimethylaminopiperidine are used to replace 3,3-difluoropyrrolidine, and then a condensation reaction is carried out under HATU conditions, followed by BH3-THF reduction, and finally condensation with compound I-5-1 under EDCI conditions to prepare compounds C-2 to C-15;

[0218] Using compound III-2 as the raw material, morpholine, thiomorpholine, and 4-hydroxypiperidine are used to replace 3,3-difluoropyrrolidine, respectively, and then a condensation reaction is carried out under HATU conditions. Finally, it is condensed with compound I-5-1 under EDCI conditions to prepare compounds C-16 to C-18.

[0219] The chemical structures and ESI-MS results of the above compounds are shown in Table 2.

[0220] Table 2. Chemical structures of representative C-series target molecules

[0221]

[0222] Example 5: General method for preparing target molecules D-1 to D-6

[0223] The synthetic routes of compounds D-1 to D-6 are as follows Fig. 9 shown.

[0224] 1. Synthesis of compound D-1, the synthetic route is as follows Fig.10 As shown, the method is as follows:

[0225] (a) 5-((3,3-difluoropyrrolidin-1-yl)methyl)thiazol-2-amine (Compound IV-2-1)

[0226] 2-Amino-5-formylthiazole (IV-1, 640 mg, 5.0 mmol) and 3,3-difluoropyrrolidine (710 μL, 7.5 mmol) were dissolved in DCM (20 mL), and then 2 drops of AcOH were added and stirred at room temperature for 30 min; NaBH(OEt)3 (1.6 g, 7.5 mmol) was then added in batches and stirred at room temperature for 4 h. An appropriate amount of water was added to quench the mixture, and the mixture was extracted with DCM. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid IV-2-1 with a yield of 78%; ESI-MS: m / z=220.1 [M+H] + .

[0227] (b) N-(5-((3,3-difluoropyrrolidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound D-1)

[0228] Compound IV-2-1 (219 mg, 1.0 mmol), compound I-5-1 (270 mg, 1.0 mmol), EDCI (382 mg, 2.0 mmol) and 4-PPY (15 mg, 0.1 mmol) were dissolved in DCM (10 mL) and refluxed with stirring overnight. The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid D-1 with a yield of 69%; ESI-MS: m / z=472.1 [M+H] + .

[0229] 2. Preparation of N-(5-((4,4-difluoropiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound D-2)

[0230] Preparation of target compound D-2: Referring to the synthesis of compound D-1, 3,3-difluoropyrrolidine was replaced by 4,4-difluoropiperidine to obtain a white solid with a yield of 84%; ESI-MS: m / z = 486.1 [M+H] + .

[0231] 3. Preparation of 2-methyl-N-(5-(morpholinomethyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound D-3)

[0232] Preparation of target compound D-3 Referring to the synthesis of compound D-1, 3,3-difluoropyrrolidine was replaced by morpholine to obtain a white solid with a yield of 80%; 1 H NMR(500MHz,Chloroform-d)δ11.39(s,1H),7.85(d,J=1.8Hz,1H),7.76(dt,J=7.6,1.6Hz,1H),7.58-7.48( m,2H),7.15(s,1H),7.01(s,1H),3.68(t,J=4.6Hz,4H),3.62(s,2H),2.79(s,3H).ESI-MS:m / z=452.1[M+H] + .

[0233] 4. Preparation of 2-methyl-N-(5-(thiomorpholinomethyl)thiazol-2-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound D-4)

[0234] Preparation of target compound D-4: Referring to the synthesis of compound D-1, 3,3-difluoropyrrolidine was replaced with thiomorpholine to obtain a white solid with a yield of 77%; ESI-MS: m / z = 468.1 [M+H] + .

[0235] 5. Preparation of N-(5-((4-hydroxypiperidin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound D-5)

[0236] Preparation of target compound D-5 Referring to the synthesis of compound D-1, 3,3-difluoropyrrolidine was replaced by 4-hydroxypiperidine to obtain a white solid with a yield of 59%; ESI-MS: m / z = 466.1 [M+H] + .

[0237] 6. Preparation of N-(5-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)thiazol-2-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound D-6)

[0238] Preparation of target compound D-6: Referring to the synthesis of compound D-1, 3,3-difluoropyrrolidine was replaced by N-hydroxyethylpiperidine to obtain a white solid with a yield of 62%; ESI-MS: m / z = 495.2 [M+H] + .

[0239] Example 6: General method for preparing target molecules E-1 to E-6, F-1 to F-6, G-1 to G-6

[0240] The synthetic routes of compounds E-1 to E-6, F-1 to F-6, G-1 to G-6 are as follows Fig.11 shown.

[0241] 1. Preparation of compound E-1, the synthetic route is as follows Fig.12 As shown, the method is as follows:

[0242] (a) 5-(2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamido)isoxazole-3-carboxylic acid ethyl ester (Compound V-2)

[0243] Dissolve 5-aminoisoxazole-3-carboxylic acid ethyl ester (V-1, 312 mg, 2.0 mmol), compound I-5-1 (520 mg, 2.0 mmol), EDCI (764 mg, 4.0 mmol) and 4-PPY (30 mg, 0.2 mmol) in DCM (20 mL) and stir under reflux overnight. Remove the solvent under reduced pressure, add an appropriate amount of water, extract with ethyl acetate, wash the organic layer with saturated saline solution, then dry with anhydrous Na2SO4, concentrate under reduced pressure, and obtain the white solid V-2 by column chromatography, with a yield of 87%; 1 H NMR(500MHz,DMSO-d6)δ11.99(s,1H),7.98-7.89(m,2H),7.77-7.69(m,3H),6.67(s,1 H),4.37(q,J=7.1Hz,2H),2.68(s,3H),1.33(t,J=7.1Hz,3H).ESI-MS:m / z=409.1[M+H] + .

[0244] (b) N-(3-(Hydroxymethyl)isoxazol-5-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound V-3)

[0245] At -20°C, compound V-2 (120 mg, 0.3 mmol) was dissolved in THF (5 mL), and then a THF solution of LiAlH4 (1 M, 0.6 mL, 0.6 mmol) was slowly added dropwise, and the reaction was continued for 30 min at -20°C; then 1 mL of water was slowly added dropwise to the reaction solution, and then 1 mL of a 15% aqueous solution of NaOH was added dropwise, anhydrous Na2SO4 was added, and diatomaceous earth was filtered. Part of the solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate, the organic layer was washed with a saturated saline solution, and then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid V-3 with a yield of 50%; 1 H NMR(500MHz,DMSO-d6)δ11.61(s,1H),7.97-7.89(m,2H),7.77-7.66(m,3H),6.41(s,1 H),5.47(t,J=6.2Hz,1H),4.47(d,J=6.1Hz,2H),2.68(s,3H).ESI-MS:m / z=367.1[M+H] + .

[0246] (c) N-(3-(bromomethyl)isoxazol-5-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound V-4)

[0247] Under N2 conditions, compound V-3 (366 mg, 1.0 mmol), PPh3 (446 mg, 1.7 mmol) and CBr4 (564 mg, 1.7 mmol) were dissolved in DCM (15 mL), and then 2,6-dimethylpyridine (31 μL, 0.4 mmol) was added, and the reaction was carried out at room temperature for 1 h; an appropriate amount of water was added, and the mixture was extracted with DCM. The organic layer was washed with a saturated saline solution, and then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid V-4 with a yield of 41%; 1 H NMR(500MHz,DMSO-d6)δ12.30(d,J=4.4Hz,1H),7.96-7.90(m,2H),7.77-7.68(m,3H),6.48(s,1H),4.84(s,2H),2.68(s,3H).ESI-MS:m / z=429.0[M+H] + .

[0248] (d) Synthesis of N-(3-((4,4-difluoropiperidin-1-yl)methyl)isoxazol-5-yl)-2-methyl-5-(3-(trifluoromethyl)phenyl)furan-3-carboxamide (Compound E-1)

[0249] Compound V-4 (428 mg, 1.0 mmol) and 4,4-difluoropiperidine (157 μL, 1.5 mmol) were dissolved in acetonitrile (10 mL), and then DIPEA (350 μL, 2.0 mmol) was added and stirred at room temperature overnight. The solvent was removed under reduced pressure, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, then dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was subjected to column chromatography to obtain a white solid E-1 with a yield of 83%; 1 H NMR(500MHz,Chloroform-d)δ7.93(d,J=1.5Hz,1H),7.71(dt,J=7.3,1.9Hz,1H),7.48-7.33(m,2H),6.91(s,1H),5. 69(s,1H),3.62(s,2H),2.70(ddd,J=12.3,5.8,4.9Hz,2H),2.62-2.52(m,5H),2.03(m,4H).ESI-MS:m / z=470.1[M+H] + .

[0250] 2. Preparation of target molecules E-2~E-6, F-1~F-6, G-1~G-6

[0251] Using compound V-4 as a raw material, p-hydroxypiperidine, morpholine, 4-methylpiperazine, N-hydroxyethylpiperazine, and thiomorpholine are used to replace 4,4-difluoropiperidine to prepare compounds E-2 to E-6;

[0252] Replace 5-aminoisoxazole-3-carboxylic acid ethyl ester (V-1) with 2-aminooxazole-4-carboxylic acid ethyl ester, then condense under EDCI conditions, then reduce with LiAlH4, brominate with CBr4, and finally react with 3,3-difluoropyrrolidine, 4,4-difluoropiperidine, 4-hydroxypiperidine, N-hydroxyethylpiperidine, morpholine, and thiomorpholine to produce compounds F-1 to F-6 by nucleophilic substitution reaction;

[0253] Replace 5-aminoisoxazole-3-carboxylic acid ethyl ester (V-1) with 5-amino-1,2,4-oxadiazole-3-carboxylic acid ethyl ester, then condense under EDCI conditions, then reduce with LiAlH4, brominate with CBr4, and finally react with 3-hydroxypyrrolidine, 4-hydroxypiperidine, N-hydroxyethylpiperidine, morpholine, thiomorpholine, 4,4-difluoropiperidine to produce compounds G-1 to G-6;

[0254] The chemical structures and ESI-MS results of the above compounds are shown in Table 3.

[0255] Table 3. Chemical structures of representative target molecules of the E, F, and G series

[0256]

[0257] Example 7: Experimental evaluation of antagonizing androgen receptor transcription factor activity

[0258] Detection principle: As a transcription factor, the androgen receptor needs to bind to the androgen response element to exert transcriptional activity. The promoter ARR2PB, which is strongly responsive to the androgen receptor (AR), is stably transfected into androgen-dependent prostate cancer cells (LNCaP) and connected to enhanced green fluorescent protein (eGFP) to construct a LNCaP-ARR2PB-eGFP stable expression model. After the concentration gradient test compound is administered, the fluorescence intensity value can directly reflect the transcriptional activity of AR, thereby reflecting the strength of the compound's antagonistic ability to the androgen receptor.

[0259] Detection steps: LNCaP-ARR2PB-eGFP cells were cultured in RPMI-1640 medium with 10% fetal bovine serum until 80% confluence, then subcultured and continued to be cultured in RPMI-1640 medium without androgen and 5% fetal bovine serum for 4-5 days. 4 The cells were inoculated into a 96-well plate at a density of 100 cells / well. After 24 h of cell attachment, 5 nM dihydrotestosterone (DHT) and a concentration gradient of the test compound (Examples 1-6) were given to each well. After incubation for 72 h, the fluorescence intensity value was detected by a multifunctional microplate reader (excitation light 485 nm, emission light 530 nm).

[0260] Test results: As shown in Table 4, most compounds showed strong AR transcriptional inhibitory activity, and the activity of several compounds was higher than that of enzalutamide.

[0261] Table 4. AR transcriptional inhibitory activity of representative compounds

[0262] serial number <![CDATA[IC 50 (μM)]]> serial number <![CDATA[IC 50 (μM)]]> serial number <![CDATA[IC 50 (μM)]]> A1 0.975 A2 0.025 A3 0.454 A5 0.871 A6 1.135 A7 0.213 A8 0.068 A13 0.660 A14 6.598 A15 0.288 A16 0.231 A22 1.631 A23 1.874 A25 0.279 A26 0.248 A27 0.054 A28 0.058 A29 0.035 A30 0.014 A33 0.046 A34 0.020 A35 0.006 A47 0.087 C11 96.12 D3 4.080 F5 32.08 Enzalutamide 0.159

[0263] Example 8: Testing the activity of compounds against AR F877L / T878A

[0264] Detection principle: A drug-resistant cell model based on a dual luciferase reporter system is used. By transiently co-transfecting an AR expression plasmid with F877L / T878A double mutations and a luciferase expression plasmid dependent on an AR strong promoter, the luciferase activity can directly reflect the transcription factor activity of the AR mutant. Adding the test compound to this system and detecting the change in luciferase activity can examine the activity of the test compound on AR F877L / T878A.

[0265] Detection method: In a 96-well plate with a white bottom, add 10,000 PC3 cells to each well, culture at 37°C for 24 hours, and then transfect according to the instructions of the transfection reagent. The co-transfected plasmids are plasmids expressing nuclear receptors, firefly luciferase expression plasmids that rely on the AR strong promoter for expression, and Renilla plasmids that express Renilla luciferase. 24 hours after transfection, aspirate the culture medium containing the transfection reagent and add fresh phenol red-free 1640 culture medium. Then add 2nM DHT and a concentration gradient of the compound to be tested to each well, and set up a control group. 24 hours after administration, the fluorescence value was detected according to the instructions of the dual luciferase reporter system, and the compound effect was calculated. IC 50 The values ​​were obtained by fitting with Graphpad Prism 8.0.2 software.

[0266] Test results: As shown in Table 5, multiple compounds showed antagonistic activity against the ARF877L / T878A resistant cell model.

[0267] Table 5. Activity of representative compounds against AR F877L / T878A resistance model

[0268] serial number <![CDATA[IC 50 (μM)]]> serial number <![CDATA[IC 50 (μM)]]> serial number <![CDATA[IC 50 (μM)]]> A2 0.380 A7 0.334 A8 1.435 A15 0.804 A27 0.063 A28 1.450 A29 0.092 A30 0.258 A33 0.323 A34 0.124 A35 0.284 A47 1.423 Enzalutamide Excited Darolutamide 1.219

[0269] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A furanamide compound having a general structural formula as shown in formula (I) or a pharmaceutically acceptable salt thereof, in, R1 and R2 are selected from hydrogen, halogen, nitro, cyano, hydroxyl, amino, C 1-3 Alkyl, C 1-3 Fluorinated alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkoxy, C 1-3 Alkylamino, C 1-3 Dialkylamino, C 3-6 Cycloalkylamino, C 1-3 Alkylsulfone group; R3 is selected from hydrogen, C 1-4 alkyl; When X is O, Y and Z are selected from CH and N respectively, and at least one of Y and Z is N; When X is S, Y is CH, and Z is N; When X is N, Y is N or CH, and Z is S; L is selected from -CH2-, -CO-; G is selected from hydrogen, halogen, hydroxyl, C 1-4 Alkyl, C 1-4 Fluorinated alkyl, -NR4R5, -NH(CH2) n NR4R5, n = 1-3; R4 and R5 are independent of each other, may be the same or different, and are selected from hydrogen, acetyl, hydroxyethyl, hydroxypropyl, methylsulfonyl, C 1-4 Alkyl, C 1-4 Fluorinated alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl; or NR4R5 is a 3-8 membered cyclic amine or substituted cyclic amine selected from morpholine, thiomorpholine, thiomorpholine dioxide, piperazine, pyrrolidine, piperidine, and the substituent is selected from hydrogen, halogen, amino, cyano, isopropyl, acetyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, C 1-6 Alkyl, C 1-6 Fluorinated alkyl, C 1-6 Alkoxy, C 1-6 Fluorinated alkoxy, C 3-8 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Dialkylamino.

2. The furanamide compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R1 and R2 are selected from H, F, Cl, Br, NO2, CN, CH3, CF3, CF3CH2, OCH3, OCHF2, OCF3, OCH2CHF2, OCH2CF3 respectively; R3 is selected from H, CH3, CH2CH3; Selected from L is selected from -CH2-, -CO-; G is selected from H, F, CH3, CH2CH3, CF3, NH2, NHCH3, N(CH3)2, N(CH2CH3)2, OH, OCH3, OCH2CH3, 3. The furanamide compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: The structural formula of the compound is shown in any one of A-1 to A-57, B-1 to B-18, C-1 to C-18, D-1 to D-6, E-1 to E-6, F-1 to F-6, and G-1 to G-6, 4. The furanamide compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: The pharmaceutically acceptable salts include organic acid salts, inorganic acid salts, organic alkali salts, and inorganic alkali salts; the organic acid salts include oxalates, lactates, p-toluenesulfonates, malates, citrates, fumarates, camphorsulfonates, and methanesulfonates; the inorganic acid salts include nitrates, sulfates, hydrohalides, and phosphates; the organic alkali salts include sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, triethylamine, and tert-butylamine; the inorganic alkali salts include sodium hydroxide, potassium hydroxide, and lithium hydroxide.

5. A polymorph of the furanamide compound or its salt or its solvate as claimed in any one of claims 1 to 4.

6. Use of the furanamide compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, or the polymorph according to claim 5 in the preparation of an androgen receptor antagonist.

7. Use of the furanamide compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, or the polymorph according to claim 5 in the preparation of a drug for treating prostate cancer, breast cancer, or ovarian cancer.

8. A pharmaceutical composition, characterized in that It contains a therapeutically effective amount of one or more furanamide compounds according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, or a polymorph according to claim 5, and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition according to claim 8, characterized in that The pharmaceutical composition is in the form of capsules, powders, tablets, granules, pills, injections, syrups, oral liquids, inhalants, ointments, suppositories or patches.

Citation Information

Patent Citations

  • Thiadiazole amide compound and application thereof

    CN113444081A